Modality
Multispecific
MOA
AuroraAi
Target
TROP-2
Pathway
T-cell
UCMM
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
Jun 2024
→ Nov 2027
Phase 1Current
NCT07473684
64 pts·MM
2024-06→2027-11·Active
64 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-011.6y awayInterim· MM
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Active
Catalysts
Interim
2027-11-01 · 1.6y away
MM
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07473684 | Phase 1 | MM | Active | 64 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 |